Ennov a Recognized Vendor in 4 Different Technology Areas
Paris, France & Greensboro, USA – September 9th 2016
Ennov today announced it has been listed four times by Gartner as a vendor in the 2016 “Hype Cycle for Life Science Research and Development”*, and twice in the 2016 “Hype Cycle for Life Sciences”**.
This recognizes the relevance of Ennov’s products in the EDMS, RIM and Pharmacovigilance categories. The reports are available on the Gartner website at:
According to Gartner, Ennov is a sample vendor for the four following product categories in Life Science:
- SaaS-Regulated EDMS (pages 23/24)
- Global Regulatory Information Management (pages 67/68)
- Global Pharmacovigilance/Safety/AERS (pages 71 to 73)
- eTMF (electronic trial master file) (pages 60 to 63)
SaaS-Regulated EDMS and eTMF are considered in the study as high benefit technologies, with 2 to 5 years to mainstream adoption in the Life Sciences sector.
Global Regulatory Information Management is considered in the study as a moderate benefit technology, with 2 to 5 years to mainstream adoption in the Life Sciences sector.
Global Pharmacovigilance/Safety/AERS is considered in the study as a moderate benefit technology, with less than 2 years to mainstream adoption in the Life Sciences sector.
About the Hype Cycle for Life Sciences
The Gartner Hype Cycle studies assess the impact of emerging technologies for a specific market. Relevant technologies are positioned through their:
- Development stage (Innovation Trigger, Peak of Inflated Expectations, Trough of Disillusionment and Plateau of Productivity)
- Number of years to mainstream adoption
- Average benefit for the industry (low, moderate, high, transformational)
- Market penetration
- Maturity level
A limited number of sample vendors are mentioned in each technology area.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Ennov provides a suite of software that enable Life Science companies to manage their regulated contents in an efficient way. This suite comprises software for the management of Quality, Pharmacovigilance, Regulatory and Clinical contents and processes.
Ennov has more than 150 Life Science customers in more than 10 countries, and more than 100,000 users. Pharmaceutical & biotech, medical device, cosmetics, specialty chemical and CRO companies trust Ennov’s solutions for the improvement of their regulated content management.
Prominent Ennov customers include Caligor RX, Ceva, Horiba, Merck, Septodont, Virbac, Innothera, Air Liquide, Alchem, BASF, Charles River, GSK, Linde, Novartis, Supersonic Imagine, Transgene, Debiopharm, Unither. Please visit us at https://en.ennov.com
* Hype Cycle for Life Science Research and Development, 2016
Published: 19 July 2016
Analyst(s): Michael Shanler
** Hype Cycle for Life Sciences, 2016
Published: 19 July 2016
Analyst(s): Michael Shanler, Stephen Davies
Olivier Pâris, Ennov